PMDA drug package insert
レボセチリジン塩酸塩錠5mg「フェルゼン」
PMDA Prescription drug · 株式会社フェルゼンファーマ · package insert Nov 20, 2023
Key facts
| Brand names | レボセチリジン塩酸塩錠5mg「フェルゼン」 |
|---|---|
| Nonproprietary names | レボセチリジン塩酸塩 |
| Companies | 製造販売元／株式会社フェルゼンファーマ |
| Product type | Prescription drug |
| Therapeutic category | 持続性選択H1受容体拮抗・アレルギー性疾患治療剤 |
| Therapeutic category codes | 87449 |
| YJ codes | 4490028F1191 |
| Approval numbers | 30200AMX00165000 |
| Package insert edition | 第1版 |
| Package insert date | Nov 20, 2023 |
| PMDA document key | 671940_4490028F1191_1 |
| PMDA company code | 671940 |
At a glance
- 1–9 Package insert revisions
- 1–9 Related PMDA documents
- None Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: